Zymeworks Inc.
NASDAQ:ZYMEBiotechnology
-$0.38 today
- Market cap
- $1.81B
- Beta
- 1.14
- P/E (TTM)
- -16.6
- EPS (TTM)
- -$1.37
Volume 1.02M
Average 0.71M
ZYME Total Current Liabilities
All obligations due within one year.
Zymeworks Inc.NASDAQ: ZYME
Total Current Liabilities · Q3 FY2026 · quarter ended Sep 2026
Total current liabilities rises 284.0% from a year ago
Total current liabilities stood at $161.46M at the end of Q3 FY2026, up 284.0% from a year earlier and up 241.8% from the prior quarter. Over 3 fiscal years it compounded at -23.8% a year.
Context
- Total current liabilities amounted to 13.7% of total assets at the end of Q3 FY2026, up 3.1 pp from a year earlier.
- Total current liabilities increased in 1 of the last 3 fiscal years.
- FY2025 was the lowest annual figure in the 4 fiscal years shown.
What to watch
Whether total current liabilities keeps rising in the next quarterly balance sheet after a +284.0% change from a year earlier.
Sources:Balance SheetText generated from reported figures; not investment advice.
Total Current Liabilities history
USD · from the balance sheet
- Latest · FY2025
- 42.32M USD
- Year-over-year change
- -52.1%
- 4-year CAGR
- -12.4%
| Period | Period end | Total Current Liabilities | YoY change |
|---|---|---|---|
| FY2025 | 2025-12-31 | 42.32M | -52.1% |
| FY2024 | 2024-12-31 | 88.29M | +58.3% |
| FY2023 | 2023-12-31 | 55.76M | -41.7% |
| FY2022 | 2022-12-31 | 95.63M | +33.1% |
| FY2021 | 2021-12-31 | 71.85M | — |
Total Current Liabilities vs competitors
How ZYME compares with its peers on the latest reported figures
- ZYME's Sep 2026 total current liabilities of $161.46M is the highest of the 11 companies compared; the peer median is $50.74M.
- Its year-over-year change of +284.0% is the 2nd highest of 11, against a peer median of +23.6%.
- Total current liabilities amounts to 13.7% of total assets for ZYME, versus a peer median of 11.1%.
| Company | Period | Latest balance | YoY | 3-year CAGR | % of assets |
|---|---|---|---|---|---|
| Sep 2026 | $161.46M | +284.0% | -23.8% | 13.7% | |
| Aug 2026 | $130.74M | +58.8% | +7.0% | 10.9% | |
| Mar 2026 | $95.94M | +73.0% | -3.9% | 44.0% | |
| Jun 2026 | $81.87M | -14.8% | +14.5% | 11.3% | |
| Mar 2026 | $67.63M | +17.0% | -5.0% | 23.2% | |
| Sep 2026 | $60.52M | +30.2% | +39.9% | 8.4% | |
| Sep 2026 | $40.97M | +30.3% | +83.1% | 8.1% | |
| Mar 2026 | $34.02M | -32.2% | -32.7% | 9.5% | |
| Mar 2026 | $22.04M | +5.0% | +23.7% | 15.1% | |
| Mar 2026 | $20.18M | +7.7% | -4.7% | 11.3% | |
| Mar 2026 | $14.19M | +442.4% | +59.6% | 7.1% | |
| Peer median (excluding ZYME) | $50.74M | +23.6% | +10.7% | 11.1% | |
Competitors are the stored peer set for ZYME. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.
Balance Sheet
Metric | FY2021 Dec 2021 | FY2022 Dec 2022 | FY2023 Dec 2023 | FY2024 Dec 2024 | FY2025 Dec 2025 |
|---|---|---|---|---|---|
| Cash & Equivalents | 201.87M | 400.91M | 157.56M | 66.1M | 41.16M |
| Short-term Investments | 50.74M | 91.32M | 216.77M | 159.67M | 187.64M |
| Net Receivables | 15.61M | 33.4M | 19.48M | 55.82M | 4.64M |
| Inventory | 0 | 0 | 0 | 0 | 0 |
| Other Current Assets | 0 | 19.07M | 19.12M | 18.86M | 0 |
| Total Current Assets | 288.22M | 544.71M | 412.93M | 300.45M | 233.44M |
| Property, Plant & Equipment (Net) | 49.77M | 47.65M | 37.54M | 34.32M | 0 |
| Goodwill | 12.02M | 12.02M | 12.02M | 12.02M | 12.02B |
| Intangible Assets | 21.47M | 26.38M | 25.28M | 4.58M | 1.35B |
| Long-term Investments | 886K | 886K | 81.93M | 98.43M | 41.79M |
| Tax Assets | 3.07M | 1.35M | 3.62M | 4.39M | 0 |
| Other Non-current Assets | 13.7M | 15.74M | 7.57M | 8.92M | (13.29B) |
| Total Non-current Assets | 100.91M | 104.02M | 167.95M | 162.64M | 113.09M |
| Total Assets | 389.13M | 648.73M | 580.88M | 463.09M | 346.53M |
| Account Payables | 5.17M | 7.86M | 6.21M | 3.9M | 4.4M |
| Short-term Debt | 0 | 0 | 0 | 0 | 0 |
| Tax Payables | 0 | 17.08M | 1.81M | 1.38M | 0 |
| Deferred Revenue | 0 | 2.35M | 3.7M | 25.59M | 2.42M |
| Other Current Liabilities | 11.1M | 16.01M | 8.68M | 7.49M | 9.67M |
| Total Current Liabilities | 71.85M | 95.63M | 55.76M | 88.29M | 42.32M |
| Long-term Debt | 0 | 0 | 0 | 0 | 0 |
| Deferred Tax Liabilities | 1.57M | 1.79M | 3.3M | 4.76M | 6.03M |
| Deferred Revenue (Non-current) | 32.94M | 30.59M | 32.94M | 14.61M | 14.61M |
| Other Non-current Liabilities | 2.65M | 2.98M | 1.61M | 895K | 278K |
| Total Non-current Liabilities | 68.19M | 60.14M | 60.31M | 36.03M | 35.71M |
| Total Liabilities | 140.04M | 155.77M | 116.07M | 124.32M | 78.03M |
| Common Stock | 741.15M | 906.76M | 1.01B | 1.02B | 1.11B |
| Retained Earnings | (683.1M) | (558.76M) | (677.44M) | (830.34M) | (953.16M) |
| Accumulated OCI | (6.66M) | (6.66M) | (6.6M) | (6.95M) | (6.08M) |
| Other Stockholders Equity | 0 | 0 | 0 | 0 | 0 |
| Minority Interest | 0 | 0 | 0 | 0 | 0 |
| Total Equity | 249.09M | 492.96M | 464.81M | 338.77M | 268.5M |
| Total Debt | 32.33M | 28.11M | 26.72M | 18.51M | 18.27M |
| Net Debt | (169.53M) | (372.8M) | (130.84M) | (47.6M) | (22.89M) |
Zymeworks Inc.
NASDAQ:ZYME
Intrinsic Alpha fair value
Locked
Current Price
$26.04
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.